PharmaCyte Biotech Inc
PharmaCyte Biotech Inc (PMCB) is a clinical-stage biotechnology company developing a cellular encapsulation therapy known as "Cell-in-a-Box". The platform is being investigated for use in pancreatic cancer and as a potential treatment approach for diabetes; programmes remain in early clinical stages. With a market capitalisation of roughly $6.65 million, PharmaCyte is a very small, speculative company that can be highly volatile and subject to binary outcomes from trials, regulatory decisions and financing events. Investors should note the likelihood of further capital raises and dilution, limited liquidity in the share register, and the long timelines common to clinical development. This summary is educational and not investment advice; outcomes are uncertain and past performance is not indicative of future results. Prospective investors should research trial data, management background, cash runway and consult a qualified financial adviser about suitability for their individual circumstances.
Stock Performance Snapshot
Financial Health
PharmaCyte Biotech has a reasonable cash flow and book value, indicating stable financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PMCB
Cancer Drug Safety: Could Warnings Create Opportunities?
The FDA's decision to add its strongest safety warning to a key cancer therapy from Johnson & Johnson and Legend Biotech underscores the inherent risks of powerful new treatments. This regulatory action could boost companies developing safer alternative cancer therapies, creating a new investment opportunity in the biotech sector.
Published: October 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Cell-in-a-Box tech
A distinctive encapsulation approach may enable targeted therapies; scientific progress matters, though clinical success is far from certain.
Clinical catalysts ahead
Trial results, regulatory steps and partnership news can move the stock materially; such events can be binary and unpredictable.
Small-cap considerations
Very low market cap and limited liquidity increase volatility and the risk of dilution; suitable only for risk-tolerant investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
